LPL Financial LLC Has $1.80 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• LPL Financial LLC increased its position in Catalyst Pharmaceuticals by 28%, purchasing an additional 16,246 shares, bringing its total to 74,229 shares valued at approximately $1.8 million.
• Other large investors have also significantly increased their stakes, with 79.22% of the stock now owned by hedge funds and institutional investors.
• Analyst ratings for Catalyst Pharmaceuticals reveal a consensus rating of "Buy", with a current price target set at $33.20.

LPL Financial LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 28.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,229 shares of the biopharmaceutical company's stock after buying an additional 16,246 shares during the quarter. LPL Financial LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,800,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares in the last quarter. Hohimer Wealth Management LLC lifted its stake in Catalyst Pharmaceuticals by 3.6% during the first quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 629 shares during the period. Bank of Montreal Can lifted its stake in Catalyst Pharmaceuticals by 6.2% during the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 875 shares during the period. Illinois Municipal Retirement Fund lifted its stake in Catalyst Pharmaceuticals by 1.6% during the first quarter. Illinois Municipal Retirement Fund now owns 60,638 shares of the biopharmaceutical company's stock worth $1,470,000 after purchasing an additional 929 shares during the period. Finally, PDT Partners LLC lifted its stake in Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock worth $431,000 after purchasing an additional 1,030 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.40% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CPRX shares. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Zacks Research cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $33.20.

Catalyst Pharmaceuticals Stock Performance

CPRX traded down $0.68 during trading on Tuesday, reaching $19.94. 1,744,650 shares of the company's stock were exchanged, compared to its average volume of 1,472,679. The company's fifty day moving average price is $21.16 and its 200-day moving average price is $22.57. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The firm has a market capitalization of $2.44 billion, a PE ratio of 12.08, a P/E/G ratio of 0.84 and a beta of 0.70.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.